Patrizia Ciammella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9247543/publications.pdf

Version: 2024-02-01

430442 377514 1,308 67 18 34 citations h-index g-index papers 69 69 69 1905 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer, 2010, 68, 72-77.	0.9	268
2	Stereotactic body radiation therapy for lung metastases. Lung Cancer, 2012, 75, 77-81.	0.9	133
3	Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiation Oncology, 2012, 7, 186.	1.2	96
4	Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors. Radiation Oncology, 2014, 9, 97.	1.2	57
5	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 370-375.	0.4	46
6	The "BUONGIORNO―Project: Burnout Syndrome Among Young Italian Radiation Oncologists. Cancer Investigation, 2013, 31, 522-528.	0.6	41
7	Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). Journal of Neuro-Oncology, 2019, 142, 59-67.	1.4	37
8	Radiomic Profiling of Head and Neck Cancer: ¹⁸ F-FDG PET Texture Analysis as Predictor of Patient Survival. Contrast Media and Molecular Imaging, 2018, 2018, 1-8.	0.4	36
9	Late Toxicity in Children Undergoing Hematopoietic Stem Cell Transplantation with TBI-containing Conditioning Regimens for Hematological Malignancies. Strahlentherapie Und Onkologie, 2009, 185, 17-20.	1.0	31
10	Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiation Oncology, 2013, 8, 222.	1.2	30
11	Efficacy and Safety of Tadalafil 20mg on Demand vs. Tadalafil 5mg Once-a-Day in the Treatment of Post-Radiotherapy Erectile Dysfunction in Prostate Cancer Men: A Randomized Phase II Trial. Journal of Sexual Medicine, 2010, 7, 2851-2859.	0.3	28
12	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.4	28
13	The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiologia Medica, 2013, 118, 660-678.	4.7	25
14	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	1.1	24
15	Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiation Oncology, 2007, 2, 15.	1.2	23
16	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	1.2	20
17	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	0.6	18
18	Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treatment and Research Communications, 2020, 22, 100161.	0.7	18

#	Article	IF	Citations
19	Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiologia Medica, 2012, 117, 1057-1070.	4.7	17
20	The "PROCAINA (PROstate CAncer INdication Attitudes) Project―(Part II) — A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiologia Medica, 2013, 118, 1220-1239.	4.7	17
21	Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature. Reports of Practical Oncology and Radiotherapy, 2013, 18, 310-315.	0.3	17
22	Feasibility of voxel-based Dose Painting for recurrent Glioblastoma guided by ADC values of Diffusion-Weighted MR imaging. Physica Medica, 2016, 32, 1651-1658.	0.4	17
23	Extracranial metastases in secondary glioblastoma multiforme: a case report. BMC Neurology, 2020, 20, 382.	0.8	17
24	Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: A 6 year single institutional experience. Clinical Neurology and Neurosurgery, 2013, 115, 1609-1614.	0.6	16
25	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Medical Oncology, 2013, 30, 729.	1.2	15
26	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	1.1	13
27	LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016041.	0.5	12
28	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	1.0	12
29	The Role of Stereotactic Ablative Radiotherapy in Oncological and Non-Oncological Clinical Settings: Highlights from the 7 th Meeting of AIRO – Young Members Working Group (AIRO Giovani). Tumori, 2014, 100, e214-e229.	0.6	12
30	A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group). Reports of Practical Oncology and Radiotherapy, 2012, 17, 259-261.	0.3	11
31	Extraskeletal multiple myeloma presenting with an atrial mass: a case report and a review of the literature. Journal of Medical Case Reports, 2012, 6, 236.	0.4	11
32	Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis. Current Oncology, 2022, 29, 881-891.	0.9	11
33	Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation. Journal of Geriatric Oncology, 2019, 10, 770-778.	0.5	10
34	Adenoid Cystic Carcinoma/Basal Cell Carcinoma of the Prostate: Overview and Update on Rare Prostate Cancer Subtypes. Current Oncology, 2022, 29, 1866-1876.	0.9	10
35	Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer: Experience at the University of Turin. Journal of Thoracic Oncology, 2007, 2, S47.	0.5	9
36	Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2022, 198, 700-709.	1.0	9

#	Article	IF	CITATIONS
37	The Role of Interstitial Brachytherapy for Breast Cancer Treatment: An Overview of Indications, Applications, and Technical Notes. Cancers, 2022, 14, 2564.	1.7	9
38	Short-course preoperative radiotherapy combined with chemotherapy in resectable locally advanced rectal cancer: local control and quality of life. Radiologia Medica, 2013, 118, 1397-1411.	4.7	8
39	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)â€"Lung Working Group. Radiologia Medica, 2019, 124, 136-144.	4.7	8
40	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clinical Lung Cancer, 2021, 22, e767-e773.	1.1	8
41	Brain metastases from primary colorectal cancer: is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO). British Journal of Radiology, 2020, 93, 20200951.	1.0	8
42	The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project. Technology in Cancer Research and Treatment, 2016, 15, 365-376.	0.8	6
43	Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review. Cancers, 2022, 14, 2680.	1.7	6
44	Polyostotic Sclerosing Histiocytosis (Erdheim-Chester Disease) Treated with Combined Vertebroplasty and Radiation Therapy. Tumori, 2010, 96, 633-636.	0.6	5
45	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	1.1	5
46	Radiotherapy Planning and Molecular Imaging in Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 204-217.	0.3	5
47	Role of modern radiation therapy in early stage Hodgkin's lymphoma: A young radiation oncologists' perspective. Reports of Practical Oncology and Radiotherapy, 2012, 17, 246-250.	0.3	4
48	Radiation therapy in small cell lung cancer: a national Italian survey. Radiologia Medica, 2018, 123, 554-560.	4.7	3
49	Renewed interest for lowâ€dose radiation therapy in follicular lymphomas: From biology to clinical applications. Hematological Oncology, 2018, 36, 723-732.	0.8	3
50	NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2018, 36, TPS4602-TPS4602.	0.8	3
51	In Reply to Adams and Kwee. International Journal of Radiation Oncology Biology Physics, 2015, 93, 725-726.	0.4	2
52	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	0.6	2
53	Advanced Radiotherapy Techniques for Mediastinal Lymphomas: Results from an Italian Survey. Hemato, 2021, 2, 496-504.	0.2	2
54	The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists. Tumori, 2014, 100, e236-42.	0.6	2

#	Article	IF	Citations
55	Surgical Strategy for Malignant Pleural Mesothelioma: Where Are We Going and What Are We Missing?. Annals of Thoracic Surgery, 2015, 100, 769-770.	0.7	1
56	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. Annals of Hematology, 2021, 100, 2547-2556.	0.8	1
57	PO-0868: A method to define isodose-based structures in Dose Painting treatment of GBM in Tomotherapy. Radiotherapy and Oncology, 2016, 119, S414-S415.	0.3	O
58	EP-1864: A 18FDG-PET texture analysis study on early stage Hodgkin Lymphoma patient outcome prediction. Radiotherapy and Oncology, 2016, 119, S879.	0.3	0
59	EP-1397: Dose painting guided by diffusion-weighted MRI applied to recurrent glioblastoma: a phase I protocol. Radiotherapy and Oncology, 2017, 123, S747.	0.3	0
60	EP-1365: F-FDG-PET/CT metabolic features as prognostic and predictive factors in lung tumors undergoing SBRT. Radiotherapy and Oncology, 2018, 127, S745.	0.3	0
61	EP-1579: SBRT for limited lymph node recurrence in patients with prostate cancer. Radiotherapy and Oncology, 2018, 127, S850.	0.3	0
62	Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists. Tumori, 2018, 104, 466-470.	0.6	0
63	First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study. Annals of Oncology, 2019, 30, $v389$.	0.6	0
64	EP-1248 Stereotactic radiotherapy for brain metastasis and systemic therapies: a safe combination?. Radiotherapy and Oncology, 2019, 133, S686.	0.3	0
65	EP-1382 Texture analysis of FDG-PET in NSCLC treated with SBRT:a validation study of two prognostic features. Radiotherapy and Oncology, 2019, 133, S754-S755.	0.3	0
66	EP-1650 Elderly glioblastoma patients:role of multidimensional assessment of frailty in predicting outcomes. Radiotherapy and Oncology, 2019, 133, S888-S889.	0.3	0
67	P1.04-41 Immunotherapy Concomitant to Radiotherapy: A Multicentric Retrospective Study on 179 Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S456.	0.5	O